Compare Incyte Corporation (INCY) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs CarMax, Inc — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while CarMax, Inc trades at $55.91 (market cap $7.93B). The key difference: Incyte Corporation is far larger — about 2.9× CarMax, Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| INCY | KMX | |
|---|---|---|
Market Cap | $23.11B | $7.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $63.53 |
52-Week Low | $67.38 | $30.88 |
Enterprise Value | $19.13B | $26.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
CarMax (KMX) trades at $57.61, up 0.49% on the day, with a bullish technical outlook supported by moving averages and a strong ADX signal. Recent Q1 2026 earnings beat expectations, driven by cost control and revenue growth, though net income margins remain thin at 0.84%. The company's four-pillar strategy focuses on volume, digital sales, and efficiency, with positive analyst coverage highlighting value and momentum potential.
The stock's upside is supported by operational improvements and insider buying, but risks include high debt levels, margin pressure, and a pending legal investigation. Analyst consensus is cautious with a $48.91 price target below the current price, suggesting limited near-term upside amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
